Skip to main content
placeholder image

Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT)

Journal Article


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2007

Citation


  • Hutson, T. E., Davis, I. D., Machiels, J. P., de Souza, P. L., Hong, B. F., Rottey, S., . . . Figlin, R. (2007). Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology, 25(18_suppl), 5031. doi:10.1200/jco.2007.25.18_suppl.5031

Web Of Science Accession Number


Start Page


  • 5031

End Page


  • 5031

Volume


  • 25

Issue


  • 18_suppl

Place Of Publication


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2007

Citation


  • Hutson, T. E., Davis, I. D., Machiels, J. P., de Souza, P. L., Hong, B. F., Rottey, S., . . . Figlin, R. (2007). Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): Interim results of a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology, 25(18_suppl), 5031. doi:10.1200/jco.2007.25.18_suppl.5031

Web Of Science Accession Number


Start Page


  • 5031

End Page


  • 5031

Volume


  • 25

Issue


  • 18_suppl

Place Of Publication